Objective To assess the cost-effectiveness of different strategies, including gonadotropin-releasing hormone agonist (GnRH-a) and oral contraceptive therapy, for the prevention of endometriosis recurrence after conservative surgery.
Introduction
Endometriosis is defined as the presence of endometrial tissue at sites other than the uterine cavity, such as the ovaries, fallopian tubes, pelvis, and abdomen. 1, 2 It affects up to 10% of the general population. 3, 4 Recent studies also showed that women with endometriosis may have an increased risk of epithelial ovarian cancer. 5 The chronic symptoms of endometriosis (dyspareunia, dysmenorrhea, chronic pelvic pain, and dyschezia) and infertility can significantly affect not only the health-related quality of life but also consume health systems' resources and increase indirect costs. 6 The aims of medical therapy are to mitigate symptoms, inhibit progression, and reduce the recurrence of symptoms and disease after surgery, which involves removing visible areas of endometriosis and restoring the anatomy. 7 Because of its proven efficacy in reducing pain, the recommendation to clinicians is to surgically manage endometriosis when it is identified by laparoscopy. 7 However, recurrence after surgery remains a challenge as up to 50% of patients will experience recurrence by the 5-year follow-up because surgery does not affect the pathogenic mechanisms of endometriosis. 8 Various options, such as oral contraceptives, have been tested after surgery to maintain the clinical effects of surgery on symptoms. 2, 8, 9 Gonadotropin-releasing hormone agonist (GnRH-a), considered the most potent compound, was superior to expectant or placebo treatment in the prevention of recurrence. 10 Compared with oral contraceptive therapy, GnRH-a therapy has better clinical benefits but is more expensive. The decision to use GnRH-a therapy should be made according to cost, availability, and the patient's preference with respect to the delivery method. 11 The only published economic analysis, done in the UK, compares different treatments for preventing the recurrence of endometriosis, including the levonorgestrel-releasing intrauterine system, depot medroxyprogesterone acetate, combined oral contraceptive pill, and no medical therapy. 12 However, we know of no studies investigating the costeffectiveness of GnRH-a therapy. Although GnRH-a is often administered as a second-line option, in recent years it has received much attention and is prescribed frequently as a first-line option after the surgery because of its improved effectiveness in reducing recurrent episodes. 1, 13 Therefore, the objective of this study was to evaluate the cost-effectiveness of GnRH-a and oral contraceptive therapy versus the usual care for ovarian, peritoneal, deep, and other endometrioses after conservative surgery. The perspective of the Chinese health care system, representative of a health-resource-limited setting, was adopted in this analysis, and only direct medical costs were considered.
Methods

Analytical overview and model structure
A mathematical model was developed to evaluate the costeffectiveness of different strategies for the prevention of recurrent endometriosis in women who have undergone conservative laparoscopic or laparotomic surgery for endometriosis. Patients were grouped according to which of the four competing strategies to prevent recurrent endometriosis they received ( Figure 1A ): 1) no medical therapy (control strategy); 2) oral contraceptive therapy (OC strategy); 3) three months of GnRH-a therapy (GnRH-3 strategy); and 4) six months of GnRH-a therapy (GnRH-6 strategy). After GnRH-a therapy was finished, we assumed that an oral contraceptive would be administered. 7 Once the endometriosis relapsed, patients were retreated with surgery and/or hormonal therapy. 1 Health and economic outcomes were projected using the Markov process ( Figure 1B) , with five exclusive health states: normal life, disease recurrence with medical therapy, disease recurrence with surgery, ovarian cancer, and death. Because endometriosis is best managed with long-term medical suppression and long-term postoperative suppression is a barrier to conception, 14 pregnancy as an outcome is not considered in an effort to focus the study aim and simplify the model. Because the GnRH-a was administered once per month for preventing the recurrence of endometriosis, the Markov cycle length was set at one month. The initial health state for all women after surgery was normal life. During each Markov cycle, patients may transition to a new health state (straight arrow). This economic analysis is based on a literature review and modelling techniques; it did not require approval by the Institutional Research Ethics Board.
The base-case initial age of the hypothetical cohort with diagnosed endometriosis that subsequently underwent conservative surgery was 32 years, which was assumed to be similar to a previous epidemiological study of Chinese women with endometriosis. 15 Because endometriosis patients usually enter regression during menopause, the current analysis assumed that menopause onset was the end of the model. 16 The base-case age of menopause in Chinese women is 50 years. 17 The impact of the base-case initial and menopause ages would be tested in the sensitivity analyses using the ranges 21-50 and 41-62 years, respectively.
The primary outcome measures were quality-adjusted life-years (QALYs) and cost, which was annually discounted at 5%, in line with the Chinese guidelines for pharmacoeconomic evaluations. 18 Incremental cost-effectiveness ratios (ICERs), presented as cost per additional QALY gained, were calculated. When the ICER was lower than the per capita gross domestic product (GDP) of China per QALY gained ($7,400/QALY), the intervention was considered to be cost-effective. 19 
Clinical data
The recurrence rates of deep, ovarian, and pelvic endometriosis after surgery were obtained from a longterm cohort study that included women with a first diagnosis of endometriosis who underwent conservative laparoscopic or laparotomic surgery for endometriosis. 20 The recurrence rates of deep, ovarian, and pelvic endometriosis are shown in the scenario where there was no medical treatment after surgery for up to four years and five to eight years, respectively. To extrapolate the effects beyond the time period of the cohort study, we assumed that the recurrent probabilities from year 9 until the end of the model were the same as with the estimated data for year eight. The relative risks (RRs) of recurrence rates for oral contraceptive therapy versus no medical prevention or for treatment with GnRH-a for 3 and 6 months were estimated based on the results of two meta-analyses 10,21 that reported odds ratios (ORs) that were converted to RRs using a well-accepted method. 22 Because the duration of efficacy of GnRH-a treatment was assumed to be no more than 1 year, 23 the current analysis, in line with expert opinion, used 6 and 12 months for the GnRH-3 and GnRH-6 strategies. Once the disease recurred, nearly 51% of patients received a second surgery, while the remainder received medical therapy. 24 For those receiving a second surgery, the analysis again followed expert opinion in assuming that the 6-month GnRH-a treatment would be prescribed to prevent further recurrence. Because of the increased risk of ovarian cancer in patients with endometriosis, the current analysis also considered the impact of this consequence. 25 The annual incidence of ovarian cancer in China is 5.35/100 000, 26 which was adjusted based on the reported OR (1.46, 95% CI: 1.31-1.63) for women with endometriosis. 25 The five-year survival rate in Chinese women with ovarian cancer was 65.3% (95% CI: 61.8-68.8). 27 A nested case-control study based on the data from the National Swedish Cancer Register showed the OR of radical extirpation of all visible endometriosis and ovarian cancer to be 0.30 (95% CI: 0.12-0.74), and simple medical therapy without surgery did not provide benefits with respect to reducing the risk. 28 Thus, we assumed the risk of ovarian cancer in women with recurrent disease was the same as for patients not receiving surgery, and women without recurrence would remain low risk throughout surgery (Table 1) .
Natural mortality could be incurred by patients with endometriosis at any point in the disease course. The model used normal lifespan values from tables for WHO member states (2011).
Cost and utility
This analysis was conducted from the perspective of the Chinese health care system. Costs are presented in 2015 US dollars ($1 US = 6.5 Chinese Yuan). Direct medical costs were incorporated into the model, including costs related to endometriosis treatment and follow-up, direct medical costs related to endometriosis comorbidities, and direct non-medical-related costs. All of the health resource unit costs were estimated from the literature and based on the local setting (Table S1 ).
The costs of GnRH-a and oral contraceptive therapy were extracted from the published literature, which incorporates cost data from nearly 130 Chinese patients with endometriosis and includes the monthly overall cost of therapeutic drugs, physician consultations, and diagnostic procedures. 29 The price of triptorelin was used to estimate the cost of the GnRH-a strategy because it is widely used in Chinese clinical practice for treating endometriosis. 30 Tibolone (1.25 mg daily) is used as the add-back therapy with GnRH analogues. Because of the lack of consensus on the duration of oral contraceptive therapy, it was assumed that patients would continue this therapy until menopause to prevent ovarian cancer. 31 The cost of surgical management for endometriosis was derived from published Chinese reports that retrospectively analyzed the costs of 1446, 4836, 305, and 255 cases of peritoneal, ovarian, deep, and other endometrioses, respectively. 32 The annual cost of managing ovarian cancer was derived from a published study that used the medical record data based on random cluster sampling. 33 Because of the absence of reported Chinese-specific utility values for endometriosis and ovarian cancer, the utility values of the three endometriosis states were derived from the study by Sanghera et al. using a 0-10 scale as a pragmatic method and collecting the data from clinicians. 12 Owing to the similar understanding and experience of this disease among clinicians worldwide, these utility scores could be assumed to represent local patients, and their uncertainties were examined in sensitivity analyses (Table S1 ). The ovarian cancer utility values were obtained from the study by Manchanda et al. 34 
Sensitivity analyses
Sensitivity analyses are typically performed to test whether a model has any structural errors (i.e., to ensure that it is robust) and to evaluate how outcomes are affected when specific variables are adjusted. One-way sensitivity analyses were carried out to test the impact of input variables into the model on the robustness of the outputs over the ranges (Tables 1 and S1 ) obtained from the published literature or assuming AE 25% of base-case values when reported data were not available. A probabilistic sensitivity analysis (second-order Monte Carlo simulation) was performed using 1000 simulations to simultaneously measure the impact of uncertainty caused by all variables. Probabilities, proportions, and utilities were assumed to follow a beta distribution, whereas cost was sampled from a triangle distribution owing to the limited number of samples for generating the cost data. The results are presented on a cost-effectiveness plane. The results projected from all 1000 simulations were used to plot willingness-to-pay (WTP) acceptability curves.
Results
Base-case analysis
In the base-case analysis (Table 2) , recurrence prevention in the GnRH-6 group compared with the other three strategies yielded the best clinical outcomes at a higher cost for all four types of endometriosis. The cumulative probabilities of ovarian cancer were reduced by approximately 0.1% in the GnRH-6 strategy compared with the others. The incremental costs of the OC, GnRH-3, and GnRH-6 strategies versus the control strategy ranged from $5,257 to $6,872, $5,467 to $7,069, $4,853 to $6,452, and $5,341 to $6,954 in patients with ovarian, peritoneal, deep, and other endometrioses, respectively, and the projected incremental gains in QALYs varied from 0.49 to 1.08, 0.51 to 1.10, 0.46 to 1.04, and 0.50 to 1.09, respectively. The ICERs of the OC, GnRH-3, and GnRH-6 strategies over the control strategy were $10,684, $7,709, and $6,364, respectively, for ovarian endometriosis; $10,630, $7,759, and $6,425, respectively, for peritoneal endometriosis; $10,589, $7,523, and $6,185, respectively, for deep endometriosis; and $10,728, $7,759, and $6,407, respectively, for other endometrioses. The GnRH-6 strategy was shown to be a dominant strategy, and the OC and GnRH-3 strategies were extended dominated (i.e., lower costs and higher ICERs) by the GnRH-6 strategy ( Figure S1 ). GnRH: gonadotropin-releasing hormone; OCT: oral contraceptive therapy; RR: risk ratio. *Probabilities were showed as per Markov cycle. **It was calculated by the following formula: Probability cycle = 1 À (1 À Cumulative probability n year ) ( 
1/n year)
.
Sensitivity analysis
In the one-way sensitivity analysis, the tornado graph (Figure S2 ) presents the results of the GnRH-6 strategy versus the control strategy for ovarian endometriosis. This type of endometriosis is the most common and the one for which the GnRH-6 strategy could yield the greatest health benefits. The sensitivity analysis revealed that the results are sensitive to the parameters associated with the remission rate and utilities. Other parameters, such as the cost of GnRH-a and oral contraceptive therapy, have no substantial impact. Pursuant to a probabilistic sensitivity analysis, acceptability curves show that recurrence prevention with the GnRH-3 strategy, when compared with no medical therapy, the OC strategy, and the GnRH-6 strategy, yield acceptable ICERs in most cases at the threshold of the Chinese percapita GDP ($7,400/QALY) for all four types of endometriosis (Figure 2 ). When three times the Chinese per capita GDP ($22,200/QALY) is used as the threshold, the GnRH-6 strategy becomes more cost-effective.
Discussion
Main findings
The results of the analysis indicate that the costs per QALY gained with the GnRH-a 6-month therapy versus no medical therapy varied from $6,185 for deep endometriosis to $6,425 for peritoneal endometriosis, both of which are below the per capita GDP of China ($7,400 in 2015) and are thus highly cost-effective according to World Health Organization (WHO) recommendations. Of the two GnRH-a strategies, the 6-month GnRH-a therapy yielded better clinical outcomes than the 3-month GnRH-a therapy, but at a higher cost. Despite its lower monthly cost, the ICERs for oral contraceptive therapy versus no medical therapy were all greater than the per capita GDP of China for all four types of endometriosis, indicating that oral contraceptive therapy is not a cost-effective option in the Chinese setting. This finding also indicates that the strategy of short-term GnRH-a combined with long-term OC therapy should be considered as an alternative in future clinical studies.
GnRH agonists have been shown to relieve the painful symptoms associated with endometriosis and to increase the duration of improvement when used for 6 months after surgery.
11 A one-way sensitivity analysis showed that the parameters related to the remission rate are the most influential. This finding suggests the ability of GnRH agonists to increase the remission rate and decrease the endometriosis recurrence rate following conservative surgery to be major determinants of clinical and economic outcomes. It could be hypothesized that maintaining the efficacy of medical or conservative surgical interventions improves their cost-effectiveness. However, more than 50% of patients will experience recurrence of pain within 5 years after medical therapy is discontinued, and the risk of recurrence will remain unchanged as it is only delayed for the duration of the therapy. 13 Currently, new regimens, such as aromatase inhibitors plus GnRH-a, are under investigation in clinical trials. 36 Other independent and influential parameters include the utility scores associated with endometriosis, which suggest that capturing accurate quality of life data is essential. 12 The model output was not sensitive to the parameter associated with ovarian cancer, although an association of a history of endometriosis with an increased risk of ovarian cancer was apparent. 25 The reason for this is possibly that the incidence of ovarian cancer is too low for the model to capture a notable impact. An appropriate surveillance plan for ovarian cancer in a population with endometriosis should be further investigated.
Strengths and limitations
There was great excitement among uterologists and patients after clinical studies demonstrated the benefits of GnRH agonists for endometriosis. However, in the context of limited health resources, the widespread use of GnRH-a increases the financial burden on patients and societies. To our knowledge, this is the first study to perform an economic evaluation of the use of oral contraceptive therapy and GnRH agonist therapy to prevent recurrent endometriosis following conservative surgery. Ovarian cancer was included in the model as one of the GnRH-3 strategy GnRH-6 strategy OC strategy Figure 2 . Cost-effectiveness acceptability curves showing the probability of four competing strategies for a range of cost-effectiveness thresholds stratified by four types of endometriosis.
outcomes. The findings indicate that postoperative medical therapy might bring about a small reduction (~0.1%) in the risk of ovarian cancer associated with endometriosis. Although the current analysis focused on the Chinese setting, the economic findings might also be relevant for decision makers from other medium-income regions, such as Brazil, Russia, Taiwan and Thailand. The evidence of improved health benefits providing by GnRH-a also might be helpful for clinicians and patients worldwide who want to decide if GnRH-a should be used as a first-line treatment.
Our study has several limitations that require consideration. First, it used clinical data derived from different published sources to evaluate the health and economic outcomes of the four strategies owing to the absence of direct head-to-head studies comparing the OC, GnRH-3, and GnRH-6 strategies with no medical therapy. This generates uncertainty regarding the findings because the data from the different sources had a high degree of heterogeneity owing to the varied study designs, patient characteristics, and dosing schedules. To test the robustness of the results, sensitivity analyses were carried out by adjusting the model variables. Future analyses should be updated if head-to-head data become available. Second, the risk of recurrence of endometriosis may be considerably different in the future, especially as new therapies are introduced. 36 To simplify our evaluation, we did not account for this issue. Nevertheless, our finding that the 6-month GnRH-a strategy is a very cost-effective alternative to the conservative treatment strategy indicates that it should be recommended and covered by health insurance. Third, we did not project the 'continuous treatment effect' approach under which active treatments, especially GnRH-a treatments, are prescribed beyond 6 months, because their efficacy and safety require evidence from further well-designed clinical studies. 9 Fourth, this study excluded indirect costs, such as the loss of productivity. One multicenter cross-sectional study showed that endometriosis can impair quality of life and work productivity. The loss of work productivity translated into significant costs per woman/week, from US $4 in Nigeria to US $456 in Italy. 37 If these indirect costs were included, the cost-effectiveness of active treatment may improve because indirect costs would be saved. Fifth, the present analysis did not account for changes in healthresource expenditures or quality of life because of treatment-related adverse events. The economic outcome of active medical prevention compared with no prevention would become less favorable if such burdens were considered; however, the available evidence suggests that active medical prevention is usually so well tolerated that women's quality of life often improves with therapy, with minimal impact on cost. [38] [39] [40] Finally, in the absence of trials comparing the efficacy of GnRH-a with the levonorgestrel-releasing intrauterine system or depot medroxy progesterone acetate in preventing the recurrence of endometriosis after surgery, the current analysis could not resolve the considerable uncertainty about what constitutes the best treatment approach.
Interpretation
The current ESHRE guidelines recommend postoperative treatment with long-term GnRH-a to reduce endometriosis-associated pain and delay recurrence. 7 Our findings indicate that this recommendation may be reasonable because the economic outcomes associated with long-term GnRH-a use are more favorable than those associated with its short-term use. Our findings were partly in accordance with those from a report recently published by Sanghera et al. 12 From a UK National Health Service perspective, the authors evaluated the cost-effectiveness of a levonorgestrelreleasing intrauterine system, depot-medroxyprogesterone acetate, and the combined oral contraceptive pill in preventing the recurrence of endometriosis after conservative surgery in primary care over a 3-year period. They found that none of the strategies was significantly beneficial compared with no treatment because of the high cost and fewer QALYs. Our results also indicate that oral contraceptive therapy is not a dominant strategy owing to its limited clinical efficacy. However, GnRH agonist therapy was not taken into account in the analysis by Sanghera et al. Our findings may provide reference information for patients, physicians, and decision-makers when therapy based on GnRH agonists is considered.
Conclusion
In conclusion, for women with endometriosis after conservative surgery in the Chinese health care setting, 6-month GnRH-a therapy is highly cost-effective compared with no medical therapy because of the favorable ICER. Owing to uncertainty regarding the findings, future analyses are necessary when more reliable data become available.
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